LA-419, a nitric-oxide donor for the treatment of cardiovascular disorders.

Abstract	LA-419, currently being developed by Lacer SA, is a thiol-containing analog of isosorbide mononitrate that is undergoing assessment in clinical trials for the treatment of chronic ischemic cardiovascular disorders. The compound was originally designed to have a reduced tendency toward tolerance sensitivity - a major limitation of established organic nitrate compounds. The rationale behind the drug design was to include an antioxidant moiety in the drug structure to combat the contribution of oxidative stress in tolerance induction. The compound is at an early stage of development, but has already provided some surprising data. First, LA-419 does not appear to require the nitroxy ester moiety for activity and its actions might not be mediated only by nitric oxide release. Second, unlike conventional nitrates, LA-419 is active in platelets, suggesting a potential role as an antithrombotic agent. Third, LA-419 has a profound impact on left ventricular hypertrophy, making the drug a plausible candidate for several additional potential therapeutic opportunities. In addition, LA-419 has demonstrated potential in the treatment of glaucoma and intestinal disorders. At the time of publication, LA-419 was in phase II clinical trials in patients with chronic ischemic cardiovascular disorders.
Authors	Ian L Megson, Stephen J Leslie
Journal	Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 10 Issue 3 Pg. 276-85 (Mar 2009) ISSN: 2040-3429 [Electronic] England
PMID	19333886 (Publication Type: Journal Article, Review)
Chemical References	Antioxidants Cardiovascular Agents Fibrinolytic Agents LA 419 Nitric Oxide Donors Isosorbide Dinitrate
Topics	Animals Antioxidants (therapeutic use) Cardiovascular Agents (adverse effects, therapeutic use) Cardiovascular Diseases (drug therapy) Disease Models, Animal Drug Tolerance Fibrinolytic Agents (therapeutic use) Humans Hypertrophy, Left Ventricular (drug therapy) Isosorbide Dinitrate (adverse effects, analogs & derivatives, therapeutic use) Myocardial Ischemia (drug therapy) Nitric Oxide Donors (adverse effects, therapeutic use) Patents as Topic Structure-Activity Relationship Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!